Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Name: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
Published: 2015
License: Public Domain

National Cancer Institute (NCI) · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory multiple myeloma, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Related documents